BIIB

Q: What is the price of Biogen (BIIB) today?

The current price of Biogen (BIIB) is $ 196.00, representing a 47.65% gain over the past year. The stock began the year trading around $ 175.99 and is currently priced at $ 196.00. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

Q: When does Biogen (BIIB) pay dividends?

Biogen (BIIB) did not pay dividends over the past year.

Q: Is Biogen (BIIB) a good investment?

Biogen (BIIB) is currently trading at $ 196.00 with a P/E ratio of 20.76. This represents a 1,993% premium compared to its historical average P/E. Over the past year, the stock has gained 47.65 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 47.65%.Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

Biogen Inc.

Price

$ 196.00

return (12m)

47.65%

p/e

20.76

p/bv

1.53

DIVIDEND YIELD

0.00%

BIIB price

Biogen

If you had invested

exposure

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

15 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment BIIB

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.83%

3 months

2.18%

1 year

47.65%

2 years

-8.59%

5 years

-26.63%

10 years

-31.66%

Fundamentals BIIB

review the fundamentals of Biogen shares

P/E

20.76

Sector: -3.88 Industry: -3.88

P/S (PSR)

2.87

Sector: -4.22 Industry: -4.22

P/BV

1.53

Sector: 1.96 Industry: 1.96

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

4.65%

Sector: -64.79% Industry: -64.79%

ROE

7.36%

Sector: -65.33% Industry: -65.33%

ROIC

6.94%

Sector: -2,907.20% Industry: -2,907.20%

NET MARGIN

13.81%

Sector: -39.82% Industry: -39.82%

GROSS MARGIN

75.49%

Sector: 36.79% Industry: 36.79%

OPERATING MARGIN

23.18%

Sector: -38.80% Industry: -38.80%

EV/EBITDA

10.77

Sector: -3.99 Industry: -3.99

EV/EBIT

14.89

Sector: -4.06 Industry: -4.06

PRICE-TO-ASSETS

0.97

Sector: 1.44 Industry: 1.44

BVPS

126.88

Sector: 1.91 Industry: 1.91

EPS

9.33

Sector: -2.12 Industry: -2.12

EQUITY-TO-ASSETS RATIO

0.63

Sector: 0.43 Industry: 0.43

LIABILITIES / ASSETS

0.37

Sector: 0.40 Industry: 0.40

CAGR REVENUE 5 YEARS

-1.98%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

-2.49%

Sector: - Industry: -

FAIR VALUE OF Biogen ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$ 196.00

Fair Value

$ 0.00

Upside/Downside Return potential.

-16.73%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals BIIB

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/bv	ROE	dy	market cap	net margin
JNJ	26.67	6.91	25.92%	2.23%	$ 561.22 B	21.83%
PFE	19.36	1.60	8.29%	6.75%	$ 145.01 B	11.83%
ABBV	105.03	-57.74	-54.98%	3.12%	$ 381.79 B	5.79%
NVO	10.53	6.36	60.40%	4.15%	$ 199.76 B	37.15%
MRK	33.87	6.59	19.45%	2.71%	$ 302.60 B	13.59%
AZN	27.89	6.11	21.93%	1.71%	$ 289.71 B	17.19%
GILD	18.11	7.12	39.33%	2.37%	$ 166.88 B	30.99%
BMY	16.66	6.03	36.19%	4.20%	$ 121.18 B	15.01%
ZTS	12.98	10.61	81.75%	2.50%	$ 34.32 B	27.79%
REGN	15.02	2.11	14.08%	0.56%	$ 66.44 B	29.65%
HALO	23.11	36.70	158.82%	0.00%	$ 8.06 B	23.13%
AMGN	23.49	19.94	84.87%	2.85%	$ 183.22 B	20.96%
MCK	19.63	-112.06	-570.98%	0.41%	$ 93.46 B	1.18%
HRMY	12.01	1.92	16.00%	0.00%	$ 1.75 B	16.20%
VRTX	25.44	5.70	22.41%	0.00%	$ 110.37 B	35.51%
CAH	30.33	-17.65	-58.20%	1.02%	$ 47.16 B	0.62%
ADMA	11.76	4.98	42.37%	0.00%	$ 1.94 B	32.43%

Stock vs Indice Comparison Tool

If you had invested

years ago

2 years

5 years

10 years

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

BIIB Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Biogen

Biogen Inc.

Average Investor10 user rating

4.0 (15 people)

United States

48 years

Founded: 1978

1991

Time since IPO - 35 years

9.100

Employees

Biogen Inc. (United States) is listed on the Nasdaq and has a market capitalization of $28.48 Billions, with shareholders equity totaling $18.65 Billions.

The company employs approximately 9.100 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Biogen Inc. reported $9.94 Billions in revenue, generating net income of $1.37 Billion.

Key financial metrics include a P/E ratio of 20.76, a price-to-book (P/B) ratio of 1.53, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker BIIB.

Market cap

$ 28.48 Billions

Net worth

$ 18.65 Billions

$ 18,651,700,000.00

Assets

$ 29.48 Billions

$ 29,483,100,000.00

Total Shares Outstanding

147.00 Millions

147,000,000

Average Daily Trading Volume

$ 1.22 Million

$ 1,219,872.00

Sector

Health Care

Industry

Biotechnology

BIIB

revenue by Business Segment Biogen

Revenue by Region Biogen

BIIB revenue and profits

Financial Results BIIB

DRAG THE FRAME TO SEE MORE DATA

BIIB cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$ 742.44 3,71% (12M)

P/E

19.63

0.41%

ROE

-570.98%

P/BV

-112.06

CAH - Cardinal Health

$ 196.80 29,21% (12M)

P/E

30.33

1.02%

ROE

-58.20%

P/BV

-17.65

JNJ - Johnson & Johnson

$ 225.33 50,12% (12M)

P/E

26.67

2.23%

ROE

25.92%

P/BV

6.91

MRK - Merck & Co.

$ 118.72 60,08% (12M)

P/E

33.87

2.71%

ROE

19.45%

P/BV

6.59

AZN - AstraZeneca

$ 185.67 31,33% (12M)

P/E

27.89

1.71%

ROE

21.93%

P/BV

6.11

ABBV - AbbVie

$ 217.72 20,70% (12M)

P/E

105.03

3.12%

ROE

-54.98%

P/BV

-57.74

NVO - Novo Nordisk

$ 45.58 --33,17% (12M)

P/E

10.53

4.15%

ROE

60.40%

P/BV

6.36

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 742.44 3,71% (12 M)

P/L

19.63

0.41%

ROE

-570.98%

P/VP

-112.06

CAH - Cardinal Health

$ 196.80 29,21% (12 M)

P/L

30.33

1.02%

ROE

-58.20%

P/VP

-17.65

JNJ - Johnson & Johnson

$ 225.33 50,12% (12 M)

P/L

26.67

2.23%

ROE

25.92%

P/VP

6.91

MRK - Merck & Co.

$ 118.72 60,08% (12 M)

P/L

33.87

2.71%

ROE

19.45%

P/VP

6.59

AZN - AstraZeneca

$ 185.67 31,33% (12 M)

P/L

27.89

1.71%

ROE

21.93%

P/VP

6.11

ABBV - AbbVie

$ 217.72 20,70% (12 M)

P/L

105.03

3.12%

ROE

-54.98%

P/VP

-57.74

NVO - Novo Nordisk

$ 45.58 --33,17% (12 M)

P/L

10.53

4.15%

ROE

60.40%

P/VP

6.36

Frequently Asked Questions

What is the price of Biogen (BIIB) today?

The current price of Biogen (BIIB) is $ 196.00, representing a 47.65% gain over the past year. The stock began the year trading around $ 175.99 and is currently priced at $ 196.00. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Biogen (BIIB) pay dividends?

Biogen (BIIB) did not pay dividends over the past year.

Is Biogen (BIIB) a good investment?

Biogen (BIIB) is currently trading at $ 196.00 with a P/E ratio of 20.76. This represents a 1,993% premium compared to its historical average P/E. Over the past year, the stock has gained 47.65 and paid $ 0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 47.65%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Biogen (BIIB) stock?

You can buy Biogen (BIIB) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol BIIB and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Biogen (BIIB) yield today?

Over the past month, Biogen (BIIB) has returned 0.83% — 47.65% over the past year, and -26.63% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Biogen (BIIB) today at the current price of $ 196.00 your total investment would be $ 19,600.00.

Based on historical performance, the investment would have grown to approximately:

$ 28,939.40 after 1 year
$ 14,380.52 after 5 years
$ 13,394.64 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

BIIB

Biogen Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment BIIB

review the fundamentals of Biogen shares

P/E

P/S (PSR)

P/BV

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Biogen

Biogen Inc.

United States

48 years

1991

9.100

PROFIT X PRICE BIIB

Financial Results BIIB

BIIB cash flow

Asset, Revenue and Profit Growth - BIIB

BIIB balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

MRK - Merck & Co.

AZN - AstraZeneca

ABBV - AbbVie

NVO - Novo Nordisk

Frequently Asked Questions